NRG Therapeutics

Our team is looking forward to attending Informa Connect #BioEurope in Stockholm next week 4-6 November. Our CEO Neil Miller will be networking and partnering, to meet with #biotech industry colleagues, investors and #Pharma partners. Get in touch if you’d like to hear more about our pipeline of first-in-class brain-penetrant, oral small molecule inhibitors of the mitochondrial permeability transition pore (#mPTP) being developed to halt the progression of #Parkinson’s, #ALS (also known as motor neuron disease #MND) and eventually other neurodegenerative diseases. Contact us via the partnering or email – info@nrgtherapeutics.com #DrugDevelopment #Biotech #Networking #NeurodegenerativeDiseases

On World Alzheimer’s day we celebrate the advances in biology and drug discovery that are delivering new treatments for Alzheimer’s and new hope for people with neurodegenerative disorders. At NRG we are energizing drug discovery in neurodegenerative diseases and advancing a pipeline of first-in-class brain-penetrant, oral small molecule drug candidates as potential disease modifying treatments based on breakthrough science in the field of mitochondrial biology. The goal for our inhibitors of the mitochondrial permeability transition pore (#mPTP) is to restore mitochondrial function and thereby slow or halt the progression of #ALS (also known as motor neurone disease #MND), Parkinson’s and eventually other neurodegenerative diseases such as Alzheimer’s. #DrugDiscovery #neuroscience #NeurodegenerativeDisorders #Innovation #WorldAlzheimer’sDay

Great article 📖 on mitochondrial therapeutics by Roohi Mariam Peter including quotes from our CEO Neil Miller and an overview of our #mPTP targeting therapeutics for #neurologicaldisorders #AML #MND #Parkinsons To find out more about our breakthrough science visit www.nrgtherapeutics.com

GRANT NEWS We are delighted announce that we have been awarded a non-dilutive grant from TARGET ALS FOUNDATION, INC in collaboration with Biospective Inc., to support our discovery proof-of-concept studies in our mitochondrial permeability transition pore (#mPTP) inhibitor drug discovery programme for a treatment for Amyotrophic Lateral Sclerosis (#ALS) (also known as Lou Gehrig’s disease or Motor Nuerone Disease, #MND).   The In Vivo Target Validation Program aims to generate high-quality data on candidate therapeutics in Biospective’s modified ALS TDP-43 mouse model, provide access to in-kind funding for a resource-intensive step of drug discovery, and accelerate the progress of candidate therapeutics from preclinical testing towards clinical trials.   NRG Therapeutics’ co-founder and CEO Dr Neil Miller said, “Preliminary experiments using a mouse model of ALS which contains the human gene for TDP-43 showed that our mPTP inihibitor candidate therapeutic reduced brain cell death. However, due to the rapid disease progression in that mouse model, a full assessment of the therapeutic potential was not possible. This project aims to evaluate NRG’s small molecule inhibitor, in the modified ALS TDP-43 mouse model that progresses more slowly. This will allow for a comprehensive assessment of the molecule’s ability to protect mitochondria, reduce brain cell death, and decrease immune system activation. Additionally, the study will measure improvements in muscle function and strength. If successful, this project will provide crucial support for advancing our mPTP inhibitor into clinical trials for ALS.”   We are one of five recipients of the 2024 In Vivo Target Validation grants. Details of the Target ALS 2024 In Vivo Target Validation grant awardess can be found HERE https://lnkd.in/ebpKCN4H See our full press release HERE https://lnkd.in/emNuMGtF   #BioTech #DrugDiscovery #Grant #NeurologicalDisorders #CNS Vad Lazari

AWARD FINALIST: We’re delighted to be recognised by Business Weekly newspaper for our progress in tackling some of the most important challenges in drug discovery research and human healthcare by leveraging breakthrough science in the field of #mitochondrial biology to identify new therapies to treat #neurodegenerative disorders such as #Parkinsons and Amyotrophic Lateral Sclerosis (#ALS)/Motor Neurone Disease (#MND). Yesterday Business Weekly announced that we have been selected as a finalist in its annual awards that recognise and celebrate achievements of companies across the East of England region in any sector. As expected, many finalists are from the biotech sector, which is strongly represented in the region. See the full shortlist of finalists here https://lnkd.in/ejim8hvh Tony Quested, Editor said ‘The competition has attracted a record entry in terms of numbers and the quality throughout the shortlist is also arguably the best we have ever seen.’ Winners will be announced during the gala dinner at Queens’ College on September 11 – good luck to all finalists. Read more about our research and pipeline here www.nrgtherapeutics.com #BioTech #DrugDiscovery #Award 

Every year the The International Alliance of ALS/MND Associations celebrates 21 June as the global day of recognition of Amyotrophic Lateral Sclerosis (#ALS)/ Motor Neurone Disease (#MND) – a disease on the increase that affects people in every country of the globe. June 21 is the solstice and hopefully a turning point each year for progress in the search for the cause, treatment and, one day a cure, of ALS/MND. This year is the 10th anniversary of the memorable #icebucketchallenge. Remarkable progress made– but not enough. At NRG we are energizing drug discovery in neurodegenerative diseases and advancing a pipeline of first-in-class brain-penetrant, oral small molecule drug candidates as potential disease modifying treatments based on breakthrough science in the field of mitochondrial biology. We are grateful for grant support from Innovate UK and, in partnership with lead applicant WEHI (Walter and Eliza Hall Institute of Medical Research) from FightMND, for our #MND #DrugDiscovery programme. The goal for our inhibitors of the mitochondrial permeability transition pore (#mPTP) is to restore mitochondrial function and thereby slow or halt the progression of Parkinson’s, ALS/MND and eventually other #NeurodegenerativeDiseases. #ALSMNDWithoutBorders #neuroscience #Innovation 

The final conference in our spring schedule! Our full founding team are crossing the pond to attend @BIO International Convention 3-6 June in San Diego. CEO Neil Miller, CSO Richard Rutter and COO Grant. Hawthorne will be networking and partnering, to meet with #biotech industry colleagues, investors and #Pharma partners. Get in touch if you’d like to hear more about our pipeline of first-in-class brain-penetrant, oral small molecule inhibitors of the mitochondrial permeability transition pore (#mPTP) being developed to halt the progression of #Parkinson’s, #ALS (also known as motor neurone disease #MND) and eventually other CNS diseases. Email – info@nrgtherapeutics.com #DrugDiscovery #Biotech #Networking #NeurodegenerativeDiseases

Our CEO Neil Miller will be in London next week at OBN (UK) Ltd #BioTrinity 2024, April 23-24 presenting on a panel, and networking with colleagues in the #biotech industry and meeting with investors and partners. Come along to the panel: Neurodegenerative & Age-Related Diseases R&D Spotlight: Science Track 1, 13.30 – 15.00, April 24 We are proud of our work to develop disease modifying therapies for #NeurodegenerativeDiseases. Get in touch if you’d like to hear more about our pipeline of first-in-class brain-penetrant, oral small molecule inhibitors of the mitochondrial permeability transition pore (#mPTP) being developed to halt the progression of #Parkinson’s, #ALS (also known as motor neurone disease #MND) and eventually other CNS diseases. Email – info@nrgtherapeutics.com #DrugDiscovery #Biotech #Networking

It’s #WorldParkinsonsDay. NRG Therapeutics is passionate about developing new medicines that bring hope to the growing number of people worldwide living with debilitating neurodegenerative disorders including Parkinson’s. We are leveraging breakthrough science in the field of mitochondrial biology to identify new therapeutic targets to treat neurodegenerative disorders. We are advancing a pipeline of potential first-in-class brain-penetrant, oral small molecule inhibitors of the mitochondrial permeability transition pore (#mPTP) with the aim of restoring mitochondrial function and slowing or halting the progression of Parkinson’s and ALS, also known as motor neurone disease (MND). Thank you to support from Parkinson's UK as investor and grant support from THE MICHAEL J FOX FOUNDATION FOR PARKINSON. #DrugDiscovery #Neuroscience #NeurodegenerativeDisorders #Parkinsons

On World Health Organization World Health Day we highlight the health challenge of neurological diseases: an estimated 1 in 3 people will be affected by a neurological condition, the leading cause of illness and disability worldwide. Over 2% of persons over 65 years are estimated to have a neurodegenerative disease. At NRG we are energizing drug discovery in neurodegenerative diseases and advancing a pipeline of first-in-class brain-penetrant, oral small molecule drug candidates as potential disease modifying treatments based on breakthrough science in the field of mitochondrial biology. The goal for our inhibitors of the mitochondrial permeability transition pore (#mPTP) is to restore mitochondrial function and thereby slow or halt the progression of Parkinson’s, #ALS (also known as motor neurone disease #MND) and eventually other neurodegenerative diseases. #MyhealthMyRight #DrugDiscovery #neuroscience #NeurodegenerativeDisorders #Innovation #WorldHealthDay